Modular Medical Announces First Patients Using Pivot Insulin Pump
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 30 2026
0mins
Modular Medical announced that the first patients have completed onboarding and training and are now actively using the Pivot tubeless insulin patch pump in real-world settings. This milestone marks the transition of the Pivot pump from development into active patient use and represents a significant step in Modular Medical's commercialization strategy. The Company will now begin collecting real world utilization data and user feedback to support broader adoption and continued product deployment optimization.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MODD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MODD
About MODD
Modular Medical, Inc. is a medical device company. The Company is focused on the design, development, and commercialization of insulin pumps using technology to increase pump adoption in the diabetes marketplace. The Company's product seeks to serve both the type 1 and type 2 diabetes markets for those individuals requiring insulin. MODD1, its product, is a high-precision pump. MODD1's features include three parts - one reusable, two disposable - snap together to form the working system; one button interface; 90-day reusable, three-day disposable; removable system, slim profile, lighter weight, and no external controller required, no charging and no battery replacement. Its pump product comprises the pump, a disposable cartridge that holds the insulin reservoir, a baseplate that affixes the pump product to the user's body and the infusion set, which includes a cannula to infuse the insulin into the body.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Modular Medical Submits Software Enhancements for Pivot Insulin Delivery System
- FDA Submission Progress: Modular Medical has submitted a series of software enhancements for its PivotTM insulin delivery system to the U.S. FDA, aiming to provide more customization options and user interface improvements, marking a significant step in the company's product development.
- User Experience Improvement: The software upgrades not only enhance the user interface but also add personalized settings, allowing patients to have a more flexible experience with the insulin delivery system, thereby increasing patient satisfaction and willingness to use.
- Optimistic Market Outlook: With the core product form cleared by the FDA and now in the market, Modular Medical plans further improvements to the Pivot platform, which is expected to attract more patients to its innovative insulin delivery technology, enhancing its competitive position in the market.
- Leadership Team Recognition: CEO Jeb Besser congratulated the team for their quick response in the FDA submission process, demonstrating the company's efficiency in technology development and market responsiveness, further solidifying its leadership position in the medical device industry.
See More
HCW Biologics Stock Surges 129% Amid Concerns
- HCW Biologics Surge: HCW Biologics Inc. (HCWB) saw its stock price soar over 129% to $2.43 on Wednesday, despite concerns about potential cash shortages, with only $1.22 million on hand as of March 31, 2026, which could hinder future R&D efforts.
- Silexion Clinical Progress: Silexion Therapeutics Corp. (SLXN) received approval from the Israeli Ministry of Health to initiate its Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer, with shares rising 96.95% to $0.53, reflecting market confidence in its development prospects.
- Immunovant Positive Data: Immunovant Inc. (IMVT) reported encouraging results from its Phase 2b trial of MVT-1402, with 72.7% of patients showing over 20% symptom improvement after 16 weeks, leading to a 35.26% stock increase to $35.56, indicating strong potential in autoimmune disease treatment.
- Modular Medical Commercialization: Modular Medical Inc. (MODD) received FDA clearance for its next-generation tubeless insulin patch pump, with initial shipments expected by the end of Q2 2026, resulting in an 18.62% stock rise to $3.95, marking a significant step towards commercialization.
See More
Modular Medical Unveils New Insulin Pump Technology
- Significant Market Need: There are 4.8 million individuals with diabetes in the U.S. requiring daily insulin, yet only 20% currently utilize insulin pumps, indicating a strong demand for innovative insulin delivery devices.
- Product Innovation Launch: Modular Medical's Pivot is the first FDA-cleared tubeless patch pump featuring a removable 3 mL reservoir and smartphone connectivity, enhancing user experience and convenience in insulin administration.
- Investor Engagement Event: CEO Jeb Besser will present at Tribe Public's webinar on May 1, 2026, discussing the company's latest developments, which is expected to attract investor interest and foster interaction between the company and its stakeholders.
- Clear Company Vision: Modular Medical aims to simplify insulin delivery through its patented technologies, striving to improve glycemic control for diabetes patients and expand diabetes care beyond just
See More
Modular Medical Prices Direct Offering of 750K Shares
- Offering Size: Modular Medical has priced a registered direct offering of 750,000 shares at $4.50 per share, which is expected to generate approximately $3.4 million in gross proceeds, providing crucial funding for the company's operations and R&D initiatives.
- Transaction Timeline: The offering is anticipated to close on or about April 21, 2026, ensuring that the company can timely utilize the funds to drive future business development and market expansion.
- Market Attention: Modular Medical has become a focal point for investors following Thursday's market close, indicating strong market interest in its financing activities, which may influence its stock price trajectory.
- Financial Transparency: The disclosure of financial information related to this offering enhances investor confidence in Modular Medical's financial health, potentially attracting more investors for future financing rounds.
See More
Modular Medical Prices Direct Offering of 750,000 Shares
- Offering Size: Modular Medical announced a direct offering of 750,000 shares at $4.50 per share, with gross proceeds estimated at approximately $3.4 million, which will provide crucial funding for the company's operations and R&D initiatives.
- Underwriter Role: Maxim Group LLC is acting as the sole placement agent for this offering, ensuring professionalism and compliance throughout the process, thereby enhancing investor confidence in the company.
- Registration Statement Background: The offering is conducted under a shelf registration statement on Form S-3 that became effective on May 22, 2025, indicating the company's compliance and transparency in the capital markets, which helps attract more investors.
- Market Outlook: Modular Medical aims to launch next-generation insulin delivery technology, focusing on improving the medication experience for diabetes patients, which is expected to drive long-term growth for the company in the medical device market.
See More
Modular Medical Secures FDA Clearance for Next-Gen Insulin Pump, Targeting $3 Billion Market
- FDA Clearance Milestone: Modular Medical's Pivot insulin pump has received FDA 510(k) clearance, marking a significant unlocking of commercial sales with initial customer shipments expected by Q2 2026, which notably reduces commercialization risks and opens a revenue growth pathway.
- Innovative Design Advantage: The Pivot pump features a first-of-its-kind removable tubeless design with a 3 mL replaceable reservoir, requiring no battery recharging and suitable for showering and sports, aimed at addressing the complexity and high costs associated with traditional insulin pumps to enhance patient adoption.
- Massive Market Potential: Approximately 70% of insulin-dependent adults remain on multiple daily injections, and the Pivot pump aims to attract this large
See More
Modular Medical Submits Software Enhancements for Pivot Insulin Delivery System
- FDA Submission Progress: Modular Medical has submitted a series of software enhancements for its PivotTM insulin delivery system to the U.S. FDA, aiming to provide more customization options and user interface improvements, marking a significant step in the company's product development.
- User Experience Improvement: The software upgrades not only enhance the user interface but also add personalized settings, allowing patients to have a more flexible experience with the insulin delivery system, thereby increasing patient satisfaction and willingness to use.
- Optimistic Market Outlook: With the core product form cleared by the FDA and now in the market, Modular Medical plans further improvements to the Pivot platform, which is expected to attract more patients to its innovative insulin delivery technology, enhancing its competitive position in the market.
- Leadership Team Recognition: CEO Jeb Besser congratulated the team for their quick response in the FDA submission process, demonstrating the company's efficiency in technology development and market responsiveness, further solidifying its leadership position in the medical device industry.
See More
HCW Biologics Stock Surges 129% Amid Concerns
- HCW Biologics Surge: HCW Biologics Inc. (HCWB) saw its stock price soar over 129% to $2.43 on Wednesday, despite concerns about potential cash shortages, with only $1.22 million on hand as of March 31, 2026, which could hinder future R&D efforts.
- Silexion Clinical Progress: Silexion Therapeutics Corp. (SLXN) received approval from the Israeli Ministry of Health to initiate its Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer, with shares rising 96.95% to $0.53, reflecting market confidence in its development prospects.
- Immunovant Positive Data: Immunovant Inc. (IMVT) reported encouraging results from its Phase 2b trial of MVT-1402, with 72.7% of patients showing over 20% symptom improvement after 16 weeks, leading to a 35.26% stock increase to $35.56, indicating strong potential in autoimmune disease treatment.
- Modular Medical Commercialization: Modular Medical Inc. (MODD) received FDA clearance for its next-generation tubeless insulin patch pump, with initial shipments expected by the end of Q2 2026, resulting in an 18.62% stock rise to $3.95, marking a significant step towards commercialization.
See More
Modular Medical Unveils New Insulin Pump Technology
- Significant Market Need: There are 4.8 million individuals with diabetes in the U.S. requiring daily insulin, yet only 20% currently utilize insulin pumps, indicating a strong demand for innovative insulin delivery devices.
- Product Innovation Launch: Modular Medical's Pivot is the first FDA-cleared tubeless patch pump featuring a removable 3 mL reservoir and smartphone connectivity, enhancing user experience and convenience in insulin administration.
- Investor Engagement Event: CEO Jeb Besser will present at Tribe Public's webinar on May 1, 2026, discussing the company's latest developments, which is expected to attract investor interest and foster interaction between the company and its stakeholders.
- Clear Company Vision: Modular Medical aims to simplify insulin delivery through its patented technologies, striving to improve glycemic control for diabetes patients and expand diabetes care beyond just
See More
Modular Medical Prices Direct Offering of 750K Shares
- Offering Size: Modular Medical has priced a registered direct offering of 750,000 shares at $4.50 per share, which is expected to generate approximately $3.4 million in gross proceeds, providing crucial funding for the company's operations and R&D initiatives.
- Transaction Timeline: The offering is anticipated to close on or about April 21, 2026, ensuring that the company can timely utilize the funds to drive future business development and market expansion.
- Market Attention: Modular Medical has become a focal point for investors following Thursday's market close, indicating strong market interest in its financing activities, which may influence its stock price trajectory.
- Financial Transparency: The disclosure of financial information related to this offering enhances investor confidence in Modular Medical's financial health, potentially attracting more investors for future financing rounds.
See More
Modular Medical Prices Direct Offering of 750,000 Shares
- Offering Size: Modular Medical announced a direct offering of 750,000 shares at $4.50 per share, with gross proceeds estimated at approximately $3.4 million, which will provide crucial funding for the company's operations and R&D initiatives.
- Underwriter Role: Maxim Group LLC is acting as the sole placement agent for this offering, ensuring professionalism and compliance throughout the process, thereby enhancing investor confidence in the company.
- Registration Statement Background: The offering is conducted under a shelf registration statement on Form S-3 that became effective on May 22, 2025, indicating the company's compliance and transparency in the capital markets, which helps attract more investors.
- Market Outlook: Modular Medical aims to launch next-generation insulin delivery technology, focusing on improving the medication experience for diabetes patients, which is expected to drive long-term growth for the company in the medical device market.
See More
Modular Medical Secures FDA Clearance for Next-Gen Insulin Pump, Targeting $3 Billion Market
- FDA Clearance Milestone: Modular Medical's Pivot insulin pump has received FDA 510(k) clearance, marking a significant unlocking of commercial sales with initial customer shipments expected by Q2 2026, which notably reduces commercialization risks and opens a revenue growth pathway.
- Innovative Design Advantage: The Pivot pump features a first-of-its-kind removable tubeless design with a 3 mL replaceable reservoir, requiring no battery recharging and suitable for showering and sports, aimed at addressing the complexity and high costs associated with traditional insulin pumps to enhance patient adoption.
- Massive Market Potential: Approximately 70% of insulin-dependent adults remain on multiple daily injections, and the Pivot pump aims to attract this large
See More
